Xu Bin

Xu Bin, MD, associate chief physician, doctoral supervisor, postdoctoral fellow at MD Anderson Cancer Center of the University of Texas, Director of the Science and Technology Department of Zhongda Hospital Affiliated to Southeast University, Deputy Director of the Institute of Urology of Southeast University, Deputy Director of General Surgery, Deputy Director of the Department of Surgery, Postdoctoral fellow at MD Anderson Cancer Center (USA), and visiting scholar at Northwestern University (USA) and New York University Roswell Park Cancer Center (USA). He has been engaged in front-line clinical, scientific research and teaching work in urology for a long time. Focus on non-coding RNA and urinary tract tumors, tumor microenvironment and treatment resistance mechanisms, and clinical multi-center research.

He is currently a member of the Basic Science Group of the Urology Branch of the Chinese Medical Association, a member of the Transformation Group of the Urology Branch of the Chinese Medical Doctor Association, a key talent for science and education to strengthen health medicine of the Jiangsu Provincial Health Commission, a “333 High-level Talent Training Project” of Jiangsu Province, a high-level talent of the “Six Talent Peaks” of Jiangsu Province, and a deputy director of scientific research and management differentiation of the Nanjing Medical Association.

He has presided over 3 National Natural Science Foundation projects, 3 provincial and ministerial level projects and 3 talent projects. His research results have won the Jiangsu Provincial Science and Technology Progress Award, the Jiangsu Provincial Medical Science and Technology Award, the Jiangsu Provincial Department of Health New Technology Introduction Award, and 8 Nanjing Excellent Natural Science Papers. He has been invited to speak many times at important meetings at home and abroad (including the 2022 European Urology Annual Meeting, the 2019 American Urology Annual Meeting, and the 2020 and 2021 National Urology Annual Meetings). Invited by the international academic journal Front Oncol to edit a special issue.

In recent years, a total of 100 SCI articles have been published, of which more than 70 papers have been published as the first (including tie) or corresponding (including tie) author, including Molecular Cancer, Journal of Hematology and Oncology, Journal of Experimental & Clinical Cancer Research, Clinical and Translational Medicine, etc. The relevant work was completed by a research group established in China, with more than 2,000 citations by others, and the highest number of citations for a single article was more than 200 times. The work has been positively evaluated by experts in related fields in China and the United States, cited as representative work by authoritative magazines such as Nature, Nat Rev Urol, and Nucleic Acids Res. It has been followed up by biomaterials and drug delivery laboratories at home and abroad, and has been applied to the development of urinary tumor treatment drugs.

Translated from the original Chinese source.